|
TN2013000195A1
|
|
Compositions and methods for treating myelofibrosis
|
|
AU2012244331A1
|
|
Heterocyclic compounds and methods of use
|
|
AU2012202928A1
|
|
Benzotriazine inhibitors of kinases
|
|
TN2011000061A1
|
|
Methods of treating thalassemia
|
|
CA2816957A1
|
|
Compositions and methods for treating myelofibrosis
|
|
AU2009279825A1
|
|
Methods of treating thalassemia
|
|
CN101983060A
|
|
Methods and compositions for treating respiratory disease
|
|
WO2009055674A1
|
|
Pyrrolopyrimidine alkynyl compounds and methods of making and using same
|
|
WO2009049028A1
|
|
Pyrrolopyrimidine compounds and their use as janus kinase modulators
|
|
WO2009046416A1
|
|
Anilinopyrimidines as jak kinase inhibitors
|
|
WO2009026346A1
|
|
Thiazolidine compounds, and methods of making and using same
|
|
WO2008008234A1
|
|
2-amino-5-substituted pyrimidine inhibitors
|
|
US2007259876A1
|
|
Kinase inhibitors and methods of use thereof
|
|
US2007149508A1
|
|
Six membered heteroaromatic inhibitors targeting resistant kinase mutations
|
|
ZA200804083B
|
|
Bi-aryl meta-pyrimidine inhibitors of kinases
|
|
CA2628283A1
|
|
Bi-aryl meta-pyrimidine inhibitors of kinases
|
|
BRPI0606172A2
|
|
methods and compositions for treating eye disorders
|
|
CN101237871A
|
|
Methods and compositions for the treatment of ocular disorders
|
|
AU2006227628A1
|
|
Pyrimidine compounds and methods of use
|
|
CN101044125A
|
|
Heterocyclic compounds and methods of use
|
